Verrica Pharmaceuticals Inc. Interest Expense Nonoperating
Verrica Pharmaceuticals Inc. (VRCA) reported Interest Expense Nonoperating of $164.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $164.00K, a 92.30% decline year-over-year.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $160.00K, a 92.74% decline year-over-year.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.31M, a 44.06% decline year-over-year.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $2.09M, a 11.87% decline year-over-year.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for fiscal 2025 was $7.74M, a 17.74% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for fiscal 2024 was $9.41M, a 137.56% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. interest expense nonoperating for fiscal 2023 was $3.96M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $164.00K 10-Q · filed 2026-08-06 | $324.00K 10-Q · filed 2026-08-06 | $1.64M derived: sum of 3 quarters · filed 2026-08-06 | $3.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $160.00K 10-Q · filed 2026-05-12 | $1.47M derived: sum of 2 quarters · filed 2026-05-12 | $3.57M derived: sum of 3 quarters · filed 2026-05-12 | $5.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.41M derived: sum of 2 quarters · filed 2026-03-11 | $5.54M derived: sum of 3 quarters · filed 2026-08-06 | $7.74M 10-K · filed 2026-03-11 |
| 2025-09-30 | $2.09M 10-Q · filed 2025-11-14 | $4.22M derived: sum of 2 quarters · filed 2026-08-06 | $6.43M 10-Q · filed 2025-11-14 | $8.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.13M 10-Q · filed 2026-08-06 | $4.33M 10-Q · filed 2026-08-06 | $6.68M derived: sum of 3 quarters · filed 2026-08-06 | $9.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.20M 10-Q · filed 2026-05-12 | $4.55M derived: sum of 2 quarters · filed 2026-05-12 | $6.93M derived: sum of 3 quarters · filed 2026-05-12 | $9.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.72M derived: sum of 2 quarters · filed 2026-03-11 | $7.09M derived: sum of 3 quarters · filed 2026-03-11 | $9.41M 10-K · filed 2026-03-11 |
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-14 | $4.74M derived: sum of 2 quarters · filed 2025-11-14 | $7.06M 10-Q · filed 2025-11-14 | $9.37M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.37M 10-Q · filed 2025-08-12 | $4.69M 10-Q · filed 2025-08-12 | $6.99M derived: sum of 3 quarters · filed 2025-08-12 | $8.65M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.32M 10-Q · filed 2025-05-13 | $4.62M derived: sum of 2 quarters · filed 2025-05-13 | $6.28M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.96M derived: sum of 2 quarters · filed 2025-03-11 | $3.96M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $1.66M 10-Q · filed 2024-11-05 | $1.66M 10-Q · filed 2024-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |